Shopping Cart
- Remove All
Your shopping cart is currently empty
Anti-PARP1 Antibody (8I163) is a Mouse antibody targeting PARP1. Anti-PARP1 Antibody (8I163) can be used in IHC-P.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 100 μL | $199 | 7-10 days |
| Description | Anti-PARP1 Antibody (8I163) is a Mouse antibody targeting PARP1. Anti-PARP1 Antibody (8I163) can be used in IHC-P. |
| Synonyms | PPOL, Poly-PARP, PARS, PARP-1, PARP, pADPRT-1, ARTD1, ADPRT1, ADPRT 1, ADPRT |
| Ig Type | Mouse IgG2a |
| Clone | 8I163 |
| Reactivity | Human |
| Specificity | Human PARP-1 |
| Verified Activity | 1. Immunochemical staining of human PARP in human testis with mouse monoclonal antibody at 1:500 dilution, formalin-fixed paraffin embedded sections. 2. Immunochemical staining of human PARP in human placenta with mouse monoclonal antibody at 1:500 dilution, formalin-fixed paraffin embedded sections. |
| Application | |
| Recommended Dose | IHC-P: 1:200-1:2000 |
| Antibody Type | Monoclonal |
| Host Species | Mouse |
| Construction | Produced in mouse immunized with E. coli-derived Human PARP / PARP1 fragment. The IgG fraction of the cell culture supernatant was purified by Protein A affinity chromatography. |
| Purification | Protein A |
| Appearance | Liquid |
| Formulation | 0.2 μm filtered solution in PBS |
| Research Background | Poly (ADP-ribose) polymerase 1(PRAP1), also known as NAD(+) ADP-ribosyltransferase 1(ADPRT), is a chromatin-associated enzyme that modifies various nuclear proteins by poly(ADP-ribosyl)ation. The ADP-D-ribosyl group of NAD+ is transferred to an acceptor carboxyl group on a histone or the enzyme itself, and further ADP-ribosyl groups are transferred to the 2'-position of the terminal adenosine moiety, building up a polymer with an average chain length of 2-3 units. The poly(ADP-ribosyl)ation modification is critical for a wide range of processes, including DNA repair, regulation of chromosome structure, transcriptional regulation, mitosis and apoptosis. PARP1 is demonstrated to mediate the poly(ADP-ribose) ation of APLF (aprataxin PNK-like factor) and CHFR (checkpoint protein with FHA and RING domains), two representative proteins involved in the DNA damage response and checkpoint regulation. Further, It has been suggested that DNA-dependent protein kinase (DNA-PK), another component of DNA repair, suppresses PARP activity, probably through direct binding and/or sequestration of DNA-ends which serve as an important stimulator for both enzymes. PARP1 inhibitors are thus proposed as a targeted cancer therapy for recombination deficient cancers, such as BRCA2 tumors.Cancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy |
| Conjucates | Unconjugated |
| Immunogen | E. coli-derived Human PARP / PARP1 fragment |
| Antigen Species | Human |
| Biology Area | Cancer Drug Targets |
| Stability & Storage | Store at 2°C-8°C for 1 month. Store at -20°C or -80°C for 12 months. Avoid repeated freeze-thaw cycles. Preservative-Free. |
| Transport | Shipping with blue ice. |

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.